Funding momentum in biotech remains selective but strong for companies with clear clinical paths. Aspen Neuroscience has closed a $115 million advance its iPSC-derived Parkinson’s therapy into later-stage development, reinforcing investor appetite for neurodegenerative programs with differentiated mechanisms. In oncology, Solve Therapeutics raised $120 million to scale its next-generation ADC platform, while Phrontline Biopharma secured $60 million to advance bispecific ADC candidates through early trials.

Neuro-focused MindImmune Therapeutics added $10.2M to its Series A as it prepares a first-in-human study targeting immune-driven Alzheimer’s pathology—signaling growing interest in inflammation-based approaches beyond classic amyloid strategies. Meanwhile, Artios Pharma is expanding Phase 2 enrollment for its ATR inhibitor across pancreatic and colorectal cancer, positioning itself for key proof-of-concept data.

Market conditions remain cautious: IPO windows are tight, valuations conservative, and early discovery startups still face headwinds. However, corporate venture arms—Novo, Lilly, Sanofi and others—are becoming dominant funders, favoring platform-rich biotechs with near-term catalysts.

Investor Takeaway: Capital is concentrating in neuro and oncology programs with clinical momentum, compelling mechanisms, and scalable platforms. Watch for updates on MindImmune’s Phase 1 start, enrollment progress from DDR-targeting programs.